Researcher looking through microscope ©Adobe Stock ImagesSilence Therapeutics (NASDAQ:SLN) shares jumped 16.2% in pre-market trading on Monday as investors positioned ahead of a conference call covering topline results from the Phase 2 SANRECO trial of divesiran, the company's lead siRNA candidate for polycythemia vera. The readout represents one of the most important near-term milestones for Silence Therapeutics, with management previously identifying the Phase 2 results as a potentially defining event for the company and the future development of divesiran. SANRECO trial puts divesiran efficacy in focusThe Phase 2 SANRECO study enrolled 48 patients with phlebotomy-dependent polycythemia vera in a randomised, double-blind, placebo-controlled trial. Investor expectations ahead of the results have been supported by encouraging findings from the earlier Phase 1 programme. Clinical progress drives sharp recovery in SLN sharesSilence Therapeutics shares reached $13.88 in pre-market trading, representing a substantial recovery from a 52-week low of $4.19.